Nektar Therapeutics (NKTR) Profit After Tax (2010 - 2026)

Nektar Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$44.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 11.75% year-over-year to -$44.9 million; the TTM figure through Mar 2026 stood at -$158.2 million (down 18.79% YoY), while the FY2025 annual figure was -$164.1 million, down 37.92% from the prior year.
• Profit After Tax for Q1 2026 stood at -$44.9 million, down from -$36.1 million in the prior quarter.
• The five-year high for Profit After Tax was $7.3 million in Q4 2024, with the low at -$160.7 million in Q2 2022.
• The 5-year median for Profit After Tax is -$45.8 million (2023), against an average of -$57.4 million.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 117.26% in 2024, then tumbled 596.89% in 2025.
• Nektar Therapeutics' Profit After Tax stood at -$59.7 million in 2022, then advanced by 29.5% to -$42.1 million in 2023, then soared by 117.26% to $7.3 million in 2024, then sank by 596.89% to -$36.1 million in 2025, then fell by 24.46% to -$44.9 million in 2026.
• Business Quant data shows NKTR's Profit After Tax at -$44.9 million in Q1 2026, -$36.1 million in Q4 2025, and -$35.5 million in Q3 2025.